Krystal Biotech’s Growth Potential Bolstered by FDA Approval and Promising Pipeline Developments

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Krystal Biotech, with a price target of $240.00.

Joseph Pantginis has given his Buy rating due to a combination of factors related to Krystal Biotech’s recent advancements. The FDA’s approval of an updated label for VYJUVEK, which now allows treatment of dystrophic epidermolysis bullosa (DEB) from birth, is a significant development. This change not only broadens the eligible patient population but also enhances treatment flexibility, as patients and caregivers can now apply VYJUVEK at home, integrating it more seamlessly into existing wound care routines. These updates, supported by positive safety and efficacy data, are expected to improve patient outcomes and quality of life by reducing clinic visits and increasing adherence.
Beyond VYJUVEK, Krystal Biotech’s pipeline shows promising progress in other areas, including oncology and aesthetics. The company is anticipating several clinical milestones by the end of 2025, such as top-line data from studies on cystic fibrosis, AATD lung disease, NK, and DEB-related eye lesions. These developments highlight Krystal’s potential for growth and innovation, reinforcing the Buy rating as the company continues to advance its therapeutic offerings.

According to TipRanks, Pantginis is an analyst with an average return of -4.0% and a 41.68% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Capricor Therapeutics, and Lineage Therap.